Premium Sotagliflozin API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Sotagliflozin (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Dual Sodium-Glucose Co-Transporter 1 and 2 (SGLT1/SGLT2) Inhibitor

Indications: Heart Failure, Cardiovascular Risk Reduction

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Sotagliflozin distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Sotagliflozin is a highly specialized, orally active small-molecule Active Pharmaceutical Ingredient (API). Within cardiovascular and metabolic pharmacology, it represents a significant advancement over standard therapies due to its unique classification as a dual sodium-glucose co-transporter 1 and 2 (SGLT1/SGLT2) inhibitor.

Unlike first-generation selective SGLT2 inhibitors, Sotagliflozin's dual mechanism targets two distinct physiological pathways. At the renal level, it inhibits the SGLT2 transporter located in the proximal renal tubule. This blockade significantly decreases the renal reabsorption of filtered glucose and sodium, promoting their excretion in the urine (glycosuria and natriuresis).

Simultaneously, Sotagliflozin inhibits the SGLT1 transporter located predominantly in the gastrointestinal tract. This local inhibition delays the absorption of dietary glucose, effectively blunting postprandial glycemic spikes.

For cardiovascular formulations, this dual action provides profound hemodynamic benefits. By increasing sodium and glucose excretion, the API reduces intravascular volume and alters cellular sodium handling, which directly decreases cardiac preload and afterload. This hemodynamic offloading allows the heart to function more efficiently, making it a critical therapeutic mechanism for patients suffering from heart failure. For formulation scientists, integrating this API allows for the development of modern cardiovascular therapeutics targeting both heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF).

Sourcing Sotagliflozin in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced cardiovascular formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing Sotagliflozin Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard batch or are scaling up a high-volume Sotagliflozin api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages or raw material shortages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending, wet granulation, and tablet compression processes.

Technical Specifications for QA & R&D

The Sotagliflozin API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2H-pyran-3,4,5-triol
• CAS Number: 1018899-04-1
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C21H25ClO5S
• Molecular Weight: 424.9 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Sotagliflozin is a pharmacologically active compound utilized in cardiovascular interventions. Facilities processing this API must enforce standard occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent chemical degradation and maintain structural integrity.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and compounding stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure weighing booths to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.